Nephrectomy for renal tumour; dissection guide and dataset

Journal of Clinical Pathology

Volumn 58, Issue 1, 2005, Pages 7-14

  Fleming, S ^a   Griffiths, D F R ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOLOGICAL THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME; UNITED KINGDOM; CANCER INVASION; EVIDENCE BASED MEDICINE; METHODOLOGY; PATHOLOGY;

CARCINOMA, RENAL CELL; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY NEOPLASMS; NEOPLASM INVASIVENESS; NEPHRECTOMY;

EID: 16644373720     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.014159     Document Type: Review

References (52)

1. Mickisch G, Carballido J, Hellsten S, et al. Guidelines on renal cell cancer. Eur Urol 2001;40:252-5.
2. Scottish Cancer Intelligence Unit. Trends in cancer survival 1971-1995. 2000. Edinburgh: Information and Statistics Division.
3. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594-9.
4. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. Trans Am Assoc Genitourin Surg 1968;60:122-9.
5. Robson G. Staging of renal cell carcinoma. Prog Clin Biol Res 1982;100:439-45.
6. Fiori E, De Cesare A, Galati G, et al. Prognostic significance of primary-tumor extension, stage and grade of nuclear differentiation in patients with renal cell carcinoma. J Exp Clin Cancer Res 2002;21:229-32.
7. Lau WK, Cheville JC, Blute ML, et al. Prognostic features of pathologic stageT1 renal cell carcinoma after radical nephrectomy. Urology 2002;59:532-7.
8. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-400.
9. Sobin LH, Wittekind Ch. Urological tumours. In: Sobin LH, Wittekind C. TNM classification of malignant tumours. Geneva: UICC, 2002:179-206.
10. Kanomata N. Impact of tumor size on the clinical outcomes of patients with Robson stage I renal cell carcinoma. Cancer 1999;86:545-6.
11. Delahunt B, Kittelson JM, McCredie MR, et al. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 2002;94:658-64.
12. Yaycioglu O, Rutman MP, Balasubramaniam M, et al. Clinical and pathologic tumor size in renal cell carcinoma; difference, correlation, and analysis of the influencing factors. Urology 2002;60:33-8.
13. Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003;170:2217-20.
14. Cheville JC, Zincke H, Lohse CM, et al. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer 2002;94:2180-4.
15. Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm better correlates with clinical outcome. J Urol 2001;166:54-8.
16. Igarashi T, Tobe T, Nakatsu HO, et al. The impact of a 4 cm cutoff point for stratification of T1N0M0 renal cell carcinoma after radical nephrectomy. J Urol 2001;165:1103-6.
17. Robson G, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
18. Bonsib SM, Gibson D, Mhoon M, et al. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 2000;24:451-8.
19. Moinzadeh A, Libertine JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor extension. Is all T3b the same? J Urol 2004;171:598-601.
20. Kim HL, Zisman A, Han KR, et al. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 2004;171:588-91.
21. Van Poppel H, Vandendriessche H, Boel K, et al. Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol 1997;158:45-9.
22. Griffiths DF, Verghese A, Golash A, et al. Contribution of grade, vascular invasion and age to outcome in clinically localized renal cell carcinoma. BJU Inf 2002;90:26-31.
23. Palapattu GS, Pantuck AJ, Dorey F, et al. Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol 2003;170:768-72.
24. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 1990;144:238-41.
25. Giberti C, Oneto F, Martorana G, et al. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol 1997;31:40-8.
26. Zisman A, Pantuck AJ, Belldegrun A. Lymph node dissection. In: Belldegrun A, Ritchie AWS, et al, eds. Renal and adrenal tumors. Oxford: Oxford University Press, 2003:318-23.
27. Blom JH, Van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC genitourinary group. Eur Urol 1999;36:570-5.
28. Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
29. Terrone C, Guercio S, De Luca S, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int 2003;91:37-40.
30. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6.
31. Ansell ID. Minimum dataset for adult renal tumour histopathology reports. London: Royal College of Pathologists, 2000.
32. Griffiths DF, Nind N, O'Brien G, et al. Evaluation of a protocol for examining nephrectomy specimens with renal cell carcinoma. J Clin Pathol 2003;56:374-7.
33. Govender D. The pathology of nephroblastoma. Curr Diagn Pathol 2000;6:45-54.
34. Zuppan CW. Handling and evaluation of pediatric renal tumors. Am J Clin Pathol 1998;109:S31-7.
35. Eble JN. Recommendations for examining and reporting tumor-bearing kidney specimens from adults. Semin Diagn Pathol 1998;15:77-82.
36. Derweesh IH, Novick AC. Nephron-sparing surgery for renal cell carcinoma. Cancer Treat Res 2003;116:93-7.
37. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001;166:6-18.
38. Ghavamian R, Zincke H. Nephron sparing surgery. In: Belldegrun A, Ritchie AWS, Figlin R, et al, eds. Renal and adrenal tumors. Oxford: Oxford University Press, 2003:309-17.
39. Castilla EA, Liou LS, Abrahams NA, et al. Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 2002;60:993-7.
40. Krejd KG, Blute ML, Cheville JC, et al. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome. Urology 2003;62:641-6.
41. Piper NY, Bishoff JT, Magee C, et al. Is a 1-CM margin necessary during nephron-sparing surgery for renal cell carcinoma? Urology 2001;58:849-52.
42. McHale T, Malkowicz SB, Tomaszewski JE, et al. Potential pitfalls in the frozen section evaluation of parenchymal margins in nephron-sparing surgery. Am J Clin Pathol 2002;118:903-10.
43. Kovacs G, Akhtor M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours [editorial]. J Pathol 1997;183:131-3.
44. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:987-9.
45. Eble JN, Sauter G, Epstein JI, et al. Tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004.
46. Fleming S, O'Donnell M. Surgical pathology of renal epithelial neoplasms: recent advances and current status. Histopathology 2000;36:195-202.
47. Leroy X, Moukassa D, Copin MC, et al. Utility of cytokeratin 7 for distinguishing chromophobe renal cell carcinoma from renal oncocytoma. Eur Urol 2000;37:484-7.
48. Mathers ME, Pollock AM, Marsh C, et al. Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology 2002;40:563-7.
49. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
50. True LD. The time for accurate Fuhrman grading of renal cell carcinomas has arrived. Am J Clin Pathol 2002;118:827-9.
51. Al Aynari M, Chen V, Salama S, et al. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med 2003;127:593-6.
52. Thomas DH, Verghese A, Kynaston HG, et al. Analysis of the prognostic implications of different tumour margin types in renal cell carcinoma. Histopathology 2003;43:374-80.